Proactive Investors - Run By Investors For Investors

Admedus receives first data from animal study on heart valve device

The TAVR heart valve device utilises the company’s ADAPT® technology.
sheep
The TAVR valve is an integral part of the company's global growth strategy

Admedus Ltd (ASX:AHZ) has received interim data from the animal study of its single-piece 3D aortic valve, which involved five sheep being implanted and monitored for five months.

Data collected from the first four sheep suggests that the device can be implanted safely and has the potential to deliver meaningful clinical benefits.

Following the positive findings in this feasibility study, Admedus now confirms it could initiate a first-in-human clinical trial earlier than expected.

The study has demonstrated that these stentless valves can be implanted with reasonable ease, without any major adverse event.

READ: Admedus secures $8.6 million as Sio Partners becomes substantial holder

Admedus chief medical officer Dr Kiran Bhirangi said: “The purpose of this feasibility study is to assess whether there is merit to progress to a larger animal study, and human clinical trials – and the results we have so far strongly support this.

“The findings are very encouraging for several reasons. The sheep model is well accepted and a good predictor of the effectiveness of the technology.”

Proven resistance to calcification

Admedus CEO Wayne Paterson said: “Calcification is a major issue for surgeons and patients today when treating valvular disease.

“Our ADAPT® tissue is the only product of its kind that has data demonstrating ten years without calcification or degradation. Combining this unique benefit with the first and only single piece 3D valve could be a major disruption in the treatment strategies for patients in the future.

Potential market leader in US$12 billion market

“ADAPT® TAVR would be a breakthrough for patients needing valve replacement.

“The TAVR market is expected to be $US12 billion by 2025. If the earlier results translate to true clinical superiority, ADAPT® TAVR could be well placed to be the market leader.

Preliminary data but well-studied

“It’s important to acknowledge the preliminary nature of this data. However, the combination of a novel single-piece 3D aortic valve and the ADAPT® technology which has been studied for ten years and is already used in over 16,000 patients is showing demonstrable clinical benefits.”

View full AHZ profile View Profile

Admedus Ltd Timeline

Related Articles

Surgery
February 21 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
Cancer cells
February 07 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use